Shire buys US drugs delivery firm for pounds 105m
Wednesday 26 February 1997
The news came as Core Group, a company specialising in sustained release drug delivery products, announced that its pounds 73m stock market flotation had been "heavily oversubscribed" at 250p a share.
To part finance the Pharmavene deal and other acquisitions being contemplated, Shire is raising pounds 11.5m by way of a one-for-10 placing and offer at 214p a share. The group is also understood to be in negotiations for the purchase of an unnamed company in Europe and a product range in the UK for total of pounds 14m.
Despite the flood of new equity, the share price dropped just 3.5p to 234p yesterday as analysts welcomed the deal and news of lower-than-expected losses of pounds 105,000 in the latest six months. Dr Rolf Stahel, Shire's chief executive, said it had effectively achieved break-even in six months, rather than the 12 months forecast by the market.
Pharmavene gives Shire another 11 potential new products, taking the pipeline to 30. The US group has created a high-throughput method of screening how well particular drug formulations penetrate human cells in the laboratory. It is applying the results in 11 projects to develop technologies for the delivery and release of drugs more effectively into the body.
The lead product is Carbatrol, a controlled release form of carbamazepine, a drug used in the treatment of epilepsy. Carbatrol, which is licensed to Athena, part of the Irish drugs delivery group Elan, could be launched later this year. If successful, it would compete directly with Novartis' Tegretol drug, which had sales of $340m in 1994.
Another product under development is a more efficient version of Glaxo Wellcome's Zovirax anti-herpes drug. But the bigger potential could come from an oral form of Calcitonin, used for the treatment of brittle bones, which could attack a world market currently put at $5bn.
Separately, Oxford Molecular, a biotechnology group, announced that it was investing pounds 500,000 in Cambridge Combinatorial, a new drug research company run by Allan Marchington, the brother of Oxford's chief executive Tony Marchington.
Oxford will take a 20 per cent stake in Cambridge. The new company plans to use combinatorial chemistry to supply potential drug prospects to other drug and biotech groups. It claims it will have an edge on similar companies by providing a narrower range of compounds for screening as new drug prospects.
- 1 President of Argentina adopts Jewish godson to 'stop him turning into a werewolf'
- 2 ALS ice bucket challenge co-founder Corey Griffin drowns, aged 27
- 3 Stoke-on-Trent becomes first British city to be classified as 'disaster resilient' by the United Nations
- 4 Sir Winston Churchill’s family begged him not to convert to Islam, letter reveals
- 5 AirAsia flight QZ8501 missing: Search for plane carrying 162 passengers from Indonesia to Singapore suspended overnight
President of Argentina adopts Jewish godson to 'stop him turning into a werewolf'
Exclusive: Abusers using spyware apps to monitor partners reaches 'epidemic proportions'
UK weather: Warning for more snow and ice as freezing temperatures and gales hit Britain
Stoke-on-Trent becomes first British city to be classified as 'disaster resilient' by the United Nations
AirAsia flight QZ8501 missing: Search for plane carrying 162 passengers from Indonesia to Singapore suspended overnight
British actor Idris Elba cannot star as James Bond because he is black, says shock jock Rush Limbaugh
Millions of Britons struggling to feed themselves and facing malnourishment
Ukip member gets into Christmas spirit with Union Flag plea to Santa 'for our country back'
Germany anti-Islam protests: 17,000 march on Dresden against 'Islamification of the West'
Nigel Farage: Ukip leader named 'Briton of the year' by The Times
Immigrants make UK racist, says Ukip councillor Trevor Shonk
iJobs Money & Business
Not specified: Selby Jennings: VP/SVP Credit Quant Top tier investment bank i...
Not specified: Selby Jennings: Quantitative Research | Global Equity | New Yor...
Not specified: Selby Jennings: SVP Model Validation This top tiered investment...
Highly Competitive: Selby Jennings: Our client, a leading European Oil trading...